ClearNote Health (formerly Bluestar Genomics) – Cancer detection company enabling people at risk for high-mortality cancers to live longer, healthier lives.

They focus on developing non-invasive tests to detect cancer through a standard blood draw earlier than existing methods by harnessing the power of epigenomics. They apply their proprietary epigenomic platform, combining biology and artificial intelligence, to identify DNA-based changes in biology as cancer develops.

With lead programs in non-invasive early detection of pancreatic and ovarian cancers in patients at the highest risk for these diseases. Headquartered in the U.S, the company’s CLIA and CAP-accredited laboratory is located in San Diego, Calif., with additional presence in the San Francisco Bay Area and internationally.


Biotechnology

Clearnote Health

Dave Mullarkey

Danielle Scelfo

Gulfem D. Guler

Anna Bergamaschi

Eric Nilson

Samuel Levy

Wayne Volkmuth

Jim Vaughn

The Product and Data Engineering team at ClearNote Health is responsible for developing and optimizing the company's non-invasive cancer detection tests. This team leverages their expertise in product development, data engineering, and AI/ML to enhance the proprietary epigenomic platform. By integrating advanced data analytics and biological insights, they aim to improve the accuracy and reliability of early cancer detection methods, particularly for high-risk pancreatic and ovarian cancers.

Product and Data Engineering

Scientists Team

Advisory Team

Clinical Research Team

Product and Data Engineering

About

Team members

Other teams at Clearnote Health

Scientists Team

Advisory Team

Clinical Research Team